Illustration for a BPC-157 evidence review, showing a knee, gut, molecule and microscope.

BPC-157 Explained: Benefits, Risks, and Why the Evidence Is Still Weak

WhatEvidence.Health · Claim Review
BPC-157 (Body Protection Compound-157) accelerates healing of injuries, repairs the gut, and offers wide-ranging health benefits in humans.
C Weak Evidence
Highly promising in animal models — but fewer than 30 humans have ever been studied. No randomised trials exist. Not approved anywhere in the world.
Evidence LevelGRADE: Very Low ●○○○
Human Studies3 published (N < 30 total)
Regulatory StatusFDA Category 2 · Unapproved globally
Last ReviewedApril 2026
Bottom Line

BPC-157 has generated one of the most extensive preclinical research programmes of any experimental peptide, with consistent healing effects seen across dozens of animal studies.1 But the leap from rat to human has not been made. Only three tiny, uncontrolled human studies exist — none with a placebo group, and none meeting the minimum evidence bar needed to recommend any treatment.657 It is actively sold online, injected by thousands of people, and promoted on social media as a near-miraculous healer.12 The honest verdict: biologically plausible, preclinically interesting, and completely unproven in people.

At a Glance
< 30
Total humans studied
0
Randomised controlled trials
80%+
Of studies from one research group
What is BPC-157?

BPC-157 is a synthetic peptide — a short chain of 15 amino acids — derived from a protein naturally found in human gastric juice. Its full name, Body Protection Compound-157, reflects its origins: researchers noticed that the stomach seems unusually resistant to its own acid, and wondered whether something in gastric secretions might be protecting tissues from damage.

That question led to a research programme beginning in the early 1990s at the University of Zagreb in Croatia.13 The peptide’s sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) bears no resemblance to any other known peptide, which makes understanding its mechanisms challenging.8 Unlike most bioactive peptides, it is unusually stable in gastric acid — meaning it survives digestion, which is why it can theoretically be taken orally.4

Today it is marketed online and in some clinics as a treatment for tendon injuries, leaky gut, inflammatory bowel disease, joint pain, muscle recovery, nerve damage, and even depression. It is sold in injectable vials, oral capsules, and nasal sprays — virtually none of which has been through formal pharmaceutical quality testing.1112

Key Findings
🔬
Animal healing — consistent positive signal Across more than 100 animal studies, BPC-157 has shown accelerated healing of tendons, ligaments, muscle, bone, and gut mucosa.14 Effects have been replicated across multiple injury models. This is a genuine and reproducible preclinical signal — but it comes overwhelmingly from one research group.13
🧪
Plausible biological mechanisms BPC-157 appears to promote tissue repair via multiple pathways: upregulation of VEGF-driven angiogenesis (new blood vessel formation), nitric oxide modulation, growth hormone receptor expression in fibroblasts, and activation of the FAK-paxillin signalling pathway that drives cell migration.23 These mechanisms are biologically credible — they are not pseudoscience.
❌
Human efficacy — not established Only three published human studies exist. The largest enrolled 16 people.6 None included a placebo control group. None were blinded. All were conducted at a single private clinic with a commercial interest in the peptide.57 These studies cannot demonstrate that BPC-157 works in humans — they are too small and too methodologically weak.
⚠️
A cancelled Phase I trial — and no explanation In 2015, a formal Phase I safety trial in 42 healthy volunteers was registered (NCT02637284).14 In 2016, the researchers cancelled submission of results without explanation. In 30 years of research, this is the closest BPC-157 ever came to proper human investigation — and it went silent. This is a significant red flag for the field.8
🛡️
Short-term safety signals are reassuring — but limited Across all three human studies (roughly 30 people), no adverse events were reported in the short term.567 A 2025 pharmacokinetic study in two adults found no harmful changes in organ function markers after IV doses up to 20mg. This is encouraging, but 30 people observed for days to weeks tells us essentially nothing about long-term safety.
🔴
Cancer risk — unresolved and biologically plausible BPC-157 promotes angiogenesis through VEGFR2 pathways.8 These same pathways are active in approximately half of human cancers, and anti-angiogenic drugs are a mainstay of oncology for good reason. No study has shown BPC-157 causes cancer — but no study has ruled it out either.910 Long-term carcinogenicity data in humans simply does not exist. This concern is theoretical but not trivial.
What the Evidence Says

The story of BPC-157’s research is unusual in modern medicine. For most experimental drugs, a promising preclinical signal in animals is followed within a decade by human trials. For BPC-157, 30 years of largely positive animal data have produced almost no human evidence at all — and what little exists is methodologically too weak to draw conclusions from.13

A 2025 systematic review in orthopaedic sports medicine examined 36 studies from 1993 to 2024 and found consistent improvements in tendon, muscle, ligament, and bone healing in animal models.1 In cell studies, BPC-157 increased fibroblast migration, enhanced tendon explant outgrowth, and upregulated growth hormone receptor expression — all credible mechanisms that would accelerate tissue repair.23 The preclinical picture is genuinely compelling. The problem is that animal research routinely fails to translate to humans, and BPC-157 has never been tested rigorously enough in people to know whether the same effects occur.

Study Type N Finding Limitations
Lee & Padgett (2021)
Alt Ther Health Med		 Retrospective case series 16 87.5% reported significant knee pain relief at 6–12 months No control N=16 Private clinic
Lee et al. (2024)
Alt Ther Health Med		 Uncontrolled pilot 12 80–100% symptom resolution in interstitial cystitis after bladder injection No placebo N=12 Private clinic
Lee & Burgess (2025)
Alt Ther Health Med		 Safety / PK study 2 No adverse events up to 20mg IV; plasma cleared within 24 hrs N=2 Days only
Vasireddi et al. (2025)
Am J Sports Med		 Systematic review (animal) 36 studies Consistent healing in musculoskeletal animal models; 1 small human study cited Animal data only COI concerns
⚠ Conflict of Interest — Critical Caveat Over 80% of the published BPC-157 literature lists Predrag Sikirić or a direct colleague as author.1013 Sikirić holds patents on BPC-157 and has financial interests in companies commercialising it. The three human studies were all conducted at a private US clinic that administers the peptide commercially.567 There is essentially no independent, non-commercially-affiliated human research on this compound. This does not mean the animal findings are fabricated — but it is an unusually concentrated conflict of interest that should significantly temper confidence in the literature.

The cancer question deserves its own mention. BPC-157 promotes new blood vessel formation (angiogenesis) — which is part of why it appears to accelerate tissue healing. But tumour growth also depends on angiogenesis. A 2024 pharmaceutical review raised this concern formally, noting that the VEGFR2 pathway BPC-157 activates is dysregulated in roughly half of human malignancies.8 The original BPC-157 research group has contested this, arguing their evidence shows BPC-157 modulates rather than globally amplifies these pathways.9 An independent Polish research group replied that the counter-argument relies on selectively chosen data from the same lab.10 Both sides agree that no long-term human cancer data exists. The concern remains unresolved.

⚠ Regulatory Position In late 2023, the US FDA classified BPC-157 as a Category 2 bulk drug substance — meaning it presents “significant safety risks” and cannot be legally compounded for human use.11 Concerns include immunogenicity, peptide impurities from unregulated manufacturing, and the absence of safety data. Any BPC-157 available for purchase online originates from unregulated sources with no quality assurance, no verified dose, and no pharmaceutical-grade testing.12
Why We Rate It This Way
Evidence Rating
C
Grade C — Weak Evidence Biologically plausible, extensive in animals, absent in humans at any meaningful scale.
  • GRADE certainty: Very Low (●○○○) — the highest study type available is an uncontrolled case series with N=166
  • No randomised controlled trials exist for any claimed human benefit112
  • The entire human evidence base totals fewer than 30 people, observed short-term567
  • Over 80% of the supportive literature comes from one research group with patent and commercial interests1013
  • A formal Phase I trial in 42 people was cancelled in 2016 without reported results — a serious concern148
  • Long-term safety data in humans does not exist; the angiogenesis/cancer question is unresolved8910
  • Animal data is consistently positive but study-to-human translation fails for many compounds, and this literature has not been independently verified at scale1

It is worth noting what a Grade C verdict does and does not mean here. BPC-157 is not homeopathy — the mechanisms are real, the animal effects are reproducible, and the biological rationale is coherent.42 The weak rating reflects the near-complete absence of human data, not an implausible concept. If proper human trials were conducted and showed the same effects seen in animals, this verdict could change significantly. The question is whether that will ever happen — and 30 years of inactivity on that front is not encouraging.13

What This Means for You

If you have heard about BPC-157 for injury recovery, gut healing, or general performance — the enthusiasm is understandable given the animal research,14 but the evidence does not currently support using it in humans for any specific purpose.12

If you are considering it anyway, the key risks to weigh are: the complete absence of long-term safety data, the theoretically plausible but unquantified cancer concern89 (especially relevant if you have any personal or family history of malignancy), and the fact that any product sold online is unregulated and of unknown purity and dose.11

This is not a compound that has been tested and found to be safe or effective in people. It is a compound that has not been tested adequately in people at all.13 That is a meaningfully different situation — and one worth understanding before making any decision.

References & Sources
  1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Orthopaedic Journal of Sports Medicine. 2025. PMC12313605 Systematic Review
  2. Hsieh MJ, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2010;110(1):309–317. PMID 21030672 In Vitro / Animal
  3. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(12):19066–19077. PMC6271067 In Vitro
  4. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533. DOI 10.3389/fphar.2021.627533 Animal Review
  5. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine. 2024;30(10):12–17. Human Pilot (N=12) PDF
  6. Lee E, Padgett B. Retrospective study of knee pain treatment with BPC-157. Alternative Therapies in Health and Medicine. 2021. Human Case Series (N=16) PDF
  7. Lee E, Burgess S. IV safety and pharmacokinetics of BPC-157. Alternative Therapies in Health and Medicine. 2025. Human Safety (N=2) PDF
  8. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. DOI 10.3390/ph18020185 Independent Review
  9. Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions. Pharmaceuticals. 2025;18(10):1450. DOI 10.3390/ph18101450 Author Reply
  10. Józwiak M, et al. Reply to Sikiric et al. BPC 157 Therapy. Pharmaceuticals. 2025;18(10):1451. DOI 10.3390/ph18101451 Independent Reply
  11. US Food and Drug Administration. 503A Bulk Drug Substances — Category 2 (BPC-157). 2023. Direct FDA page Regulatory
  12. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. 2020 (updated 2025). USADA.org Regulatory
  13. Undark / STAT News. BPC-157: The peptide with big claims and scant evidence. February 2026. STAT News Investigative Report
  14. NCT02637284. Phase I Pilot Study in Healthy Volunteers: Safety and Pharmacokinetics of PCO-02 (BPC-157). ClinicalTrials.gov. Registered 2015; results not published. ClinicalTrials.gov Cancelled Trial
Last reviewed: April 2026 · Reviewed by a practising Australian GP · WhatEvidence.Health
Disclaimer: This page is for general informational purposes only and does not constitute personal health advice. It is not a substitute for professional clinical consultation. If you have questions about your own health or are considering any supplement, peptide, or treatment, please speak with a qualified health professional. WhatEvidence.Health does not endorse any product, brand, or commercial entity referenced on this page.

Similar Posts

  • GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper)

    WhatEvidence.Health · Claim Review Topical GHK-Cu copper peptide reduces visible skin aging, including wrinkles, laxity, and uneven skin tone. C Weak Evidence Plausible – but not proven. Small human studies and cosmetic reviews suggest possible skin benefits, but the evidence is older, short-term, and not strong enough to support broad anti-aging claims. Evidence LevelGRADE: Low…

  • Retatrutide

    WhatEvidence.Health · Claim Review Retatrutide peptide causes major weight loss and improves metabolic health. B Promising Evidence Strong trial signal — not a consumer peptide. Retatrutide has caused large weight loss in clinical trials, but it is still investigational and should not be bought or injected outside a regulated clinical trial. Evidence LevelModerate for trial…